Skywater Technology: Sequencing Technology is Critical to Identify Mutations of the Virus

And Important for Epidemiologists When Tracking the Spread of Infections Through a Population Reports SkyWater Technology

Skywater Technology announced its partnership with MGI (a member of BGI Group) to supply critical components used by MGI’s DNA sequencing system DNBSEQ-T7, one of the first officially approved products by the National Medical Products Administration (NMPA – essentially China’s version of the FDA), under the emergency approval process for the coronavirus (COVID-19).

MGI, a global genomics platform company, along with its affiliates, was very quick to respond to the novel coronavirus virus and is bringing its full genomics expertise and resources to the front lines in the fight against it.

MGI has a manufacturing plant in Wuhan, China, the epicenter of the COVID-19 outbreak, where MGI delivered and deployed its NMPA-approved DNBSEQ-T7 sequencing systems for sequencing-based COVID-19 detection solutions.

SkyWater has been working with MGI for several years and supplies a component of BGI’s Flowcells (microfluidic MEMS devices). This component forms the basis for one of the consumables used in the sequencing kit in the DNBSEQ-T7 system, an ultra-high-throughput sequencing system manufactured by MGI.

At the time of this announcement, MGI is also providing automated sample preparation systems to help labs to increase the capacity to aid in more widespread and rapid screening in the U.S.

“As concerns rise about the coronavirus global pandemic, the pressure is on to enable even faster, more accessible testing. We are pleased to be working with genomics leader MGI and playing a role as a U.S. manufacturer in cutting-edge technology solutions that are making an important contribution to the detection of COVID-19,” said Thomas Sonderman, SkyWater President.

“Products from MGI and its affiliates are ready for international delivery to assist the global efforts in fighting the coronavirus pandemic, a number of which have already been sent to other countries,” said Dr. Yongwei Zhang, BGI Group VP & CEO, Americas Region. “SkyWater has been an excellent partner. We very much appreciate their support over the years, and we look forward to our ongoing partnership as we continue providing the highest quality genomic data at rapid turnaround times.”

SkyWater is certified to the ISO 13485 Quality Standard for Medical Devices to support the design, development and fabrication of DNA sequencing and other biochip applications in a wide range of emerging biomedical market segments.

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.